Home » Newsletters » BioWorld

BioWorld

June 27, 2016

View Archived Issues

BioWorld stock report for public biotechnology companies

The week's biggest gainers and losers

Money raised by biotech: Jan. 1 - June 23, 2016

Money raised by biotech in 2016 vs. 2015

Pending biopharmaceutical mergers and acquisitions

Completed biopharmaceutical mergers and acquisitions: March 1 - June 23, 2016

Top 10 biopharmaceutical M&As in 2016

Week in Washington

Word on the street

Week in review

Nanotech: Small drugs, myriad of opportunities

From cancer to psoriasis, companies are using different nanotechnology platforms to deliver drugs more effectively. Read More

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Flow Neuro wins FDA nod for at-home device for depression
BioWorld MedTech
Flow Neuroscience AB received U.S. FDA 510(k) approval for its Flow at-home brain-stimulation device to treat major depressive disorder. The wearable headset uses...